FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095340797> ?p ?o ?g. }

• W2095340797 endingPage "e206" @default.
• W2095340797 startingPage "e198" @default.
• W2095340797 abstract "Progression of chronic myelogenous leukemia (CML) to accelerated (AP) and blast phase (BP) is because of secondary molecular events, as well as additional cytogenetic abnormalities. On the basis of the detection of JAK2, CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations in myelodysplastic/myeloproliferative neoplasms, we hypothesized that they may also contribute to progression in CML. We screened these genes for mutations in 54 cases with CML (14 with chronic phase, 14 with AP, 20 with myeloid, and 6 with nonmyeloid BP). We identified 1 CBLB and 2 TET2 mutations in AP, and 1 CBL, 1 CBLB, 4 TET2, 2 ASXL1, and 2 IDH family mutations in myeloid BP. However, none of these mutations were found in chronic phase. No cases with JAK2V617F mutations were found. In 2 cases, TET2 mutations were found concomitant with CBLB mutations. By single nucleotide polymorphism arrays, uniparental disomy on chromosome 5q, 8q, 11p, and 17p was found in AP and BP but not involving 4q24 (TET2) or 11q23 (CBL). Microdeletions on chromosomes 17q11.2 and 21q22.12 involved tumor associated genes NF1 and RUNX1, respectively. Our results indicate that CBL family, TET2, ASXL1, and IDH family mutations and additional cryptic karyotypic abnormalities can occur in advanced phase CML." @default.
• W2095340797 created "2016-06-24" @default.
• W2095340797 creator A5007646752 @default.
• W2095340797 creator A5015214215 @default.
• W2095340797 creator A5021855592 @default.
• W2095340797 creator A5022299669 @default.
• W2095340797 creator A5027080346 @default.
• W2095340797 creator A5043376674 @default.
• W2095340797 creator A5050620740 @default.
• W2095340797 creator A5051134184 @default.
• W2095340797 creator A5068751884 @default.
• W2095340797 creator A5072987784 @default.
• W2095340797 creator A5078527108 @default.
• W2095340797 creator A5082944296 @default.
• W2095340797 creator A5083810250 @default.
• W2095340797 creator A5085974329 @default.
• W2095340797 creator A5088509244 @default.
• W2095340797 creator A5090305907 @default.
• W2095340797 date "2011-05-26" @default.
• W2095340797 modified "2023-10-12" @default.
• W2095340797 title "CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia" @default.
• W2095340797 cites W1964295470 @default.
• W2095340797 cites W1973415773 @default.
• W2095340797 cites W1976489834 @default.
• W2095340797 cites W1976529806 @default.
• W2095340797 cites W1976767411 @default.
• W2095340797 cites W1977590248 @default.
• W2095340797 cites W1980568348 @default.
• W2095340797 cites W1988934312 @default.
• W2095340797 cites W1994467709 @default.
• W2095340797 cites W1998191493 @default.
• W2095340797 cites W1998548151 @default.
• W2095340797 cites W1998598673 @default.
• W2095340797 cites W1999813105 @default.
• W2095340797 cites W2001048486 @default.
• W2095340797 cites W2004029643 @default.
• W2095340797 cites W2013726626 @default.
• W2095340797 cites W2025391163 @default.
• W2095340797 cites W2026310796 @default.
• W2095340797 cites W2028803880 @default.
• W2095340797 cites W2029890460 @default.
• W2095340797 cites W2031720246 @default.
• W2095340797 cites W2038244338 @default.
• W2095340797 cites W2038538605 @default.
• W2095340797 cites W2039234691 @default.
• W2095340797 cites W2040571489 @default.
• W2095340797 cites W2040827479 @default.
• W2095340797 cites W2045204068 @default.
• W2095340797 cites W2050027087 @default.
• W2095340797 cites W2052024543 @default.
• W2095340797 cites W2057360098 @default.
• W2095340797 cites W2058604302 @default.
• W2095340797 cites W2059852420 @default.
• W2095340797 cites W2061653945 @default.
• W2095340797 cites W2076142320 @default.
• W2095340797 cites W2079901663 @default.
• W2095340797 cites W2080452140 @default.
• W2095340797 cites W2082312262 @default.
• W2095340797 cites W2083109253 @default.
• W2095340797 cites W2084334750 @default.
• W2095340797 cites W2086066062 @default.
• W2095340797 cites W2089580349 @default.
• W2095340797 cites W2097743943 @default.
• W2095340797 cites W2108664872 @default.
• W2095340797 cites W2114549720 @default.
• W2095340797 cites W2119967034 @default.
• W2095340797 cites W2126817554 @default.
• W2095340797 cites W2129398278 @default.
• W2095340797 cites W2134061682 @default.
• W2095340797 cites W2137573050 @default.
• W2095340797 cites W2139255055 @default.
• W2095340797 cites W2142311991 @default.
• W2095340797 cites W2159731673 @default.
• W2095340797 doi "https://doi.org/10.1182/blood-2010-06-292433" @default.
• W2095340797 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3110035" @default.
• W2095340797 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21346257" @default.
• W2095340797 hasPublicationYear "2011" @default.
• W2095340797 type Work @default.
• W2095340797 sameAs 2095340797 @default.
• W2095340797 citedByCount "139" @default.
• W2095340797 countsByYear W20953407972012 @default.
• W2095340797 countsByYear W20953407972013 @default.
• W2095340797 countsByYear W20953407972014 @default.
• W2095340797 countsByYear W20953407972015 @default.
• W2095340797 countsByYear W20953407972016 @default.
• W2095340797 countsByYear W20953407972017 @default.
• W2095340797 countsByYear W20953407972018 @default.
• W2095340797 countsByYear W20953407972019 @default.
• W2095340797 countsByYear W20953407972020 @default.
• W2095340797 countsByYear W20953407972021 @default.
• W2095340797 countsByYear W20953407972022 @default.
• W2095340797 countsByYear W20953407972023 @default.
• W2095340797 crossrefType "journal-article" @default.
• W2095340797 hasAuthorship W2095340797A5007646752 @default.
• W2095340797 hasAuthorship W2095340797A5015214215 @default.
• W2095340797 hasAuthorship W2095340797A5021855592 @default.
• W2095340797 hasAuthorship W2095340797A5022299669 @default.
• W2095340797 hasAuthorship W2095340797A5027080346 @default.

• next